114 related articles for article (PubMed ID: 28860802)
1. Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target.
Sun M; Zhao W; Zeng Y; Zhang D; Chen Z; Liu C; Wu B
Onco Targets Ther; 2017; 10():3949-3956. PubMed ID: 28860802
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of expression of fibrous sheath interacting protein 1 in colon cancer.
Wu HY; Yang B; Geng DH
World J Gastrointest Oncol; 2020 Jun; 12(6):677-686. PubMed ID: 32699582
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway.
Sun M; Chen Z; Tan S; Liu C; Zhao W
Onco Targets Ther; 2018; 11():1961-1971. PubMed ID: 29670371
[TBL] [Abstract][Full Text] [Related]
4. Elevated fibrous sheath interacting protein 1 levels are associated with poor prognosis in non-small cell lung cancer patients.
Mao Y; Xu R; Liu X; Shi W; Han Y
Oncotarget; 2017 Feb; 8(7):12186-12193. PubMed ID: 28086239
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinicopathological significance of FSIP1 in breast cancer.
Zhang H; Luo M; Jin Z; Wang D; Sun M; Zhao X; Zhao Z; Lei H; Li M; Liu C
Oncotarget; 2015 Apr; 6(12):10658-66. PubMed ID: 25826084
[TBL] [Abstract][Full Text] [Related]
6. FSIP1 is correlated with estrogen receptor status and poor prognosis.
Li X; Song X; Ma J; Zhao Y; Jiang Q; Zhao Z; Li M
Mol Carcinog; 2020 Jan; 59(1):126-135. PubMed ID: 31713931
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
Yan M; Wang J; Ren Y; Li L; He W; Zhang Y; Liu T; Li Z
Cell Death Dis; 2019 Feb; 10(3):204. PubMed ID: 30814489
[TBL] [Abstract][Full Text] [Related]
8. Elevated mRNA level indicates FSIP1 promotes EMT and gastric cancer progression by regulating fibroblasts in tumor microenvironment.
Liu Y; Jiang X; Yan X; Yang S; Bian X; Wang Y; You Q; Zhang L
Open Med (Wars); 2024; 19(1):20240964. PubMed ID: 38737444
[TBL] [Abstract][Full Text] [Related]
9. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.
Wang Y; Kang XL; Zeng FC; Xu CJ; Zhou JQ; Luo DN
Pathol Res Pract; 2017 Jul; 213(7):766-772. PubMed ID: 28554751
[TBL] [Abstract][Full Text] [Related]
10. FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer.
Yan X; Dai J; Han Y; You Q; Liu Y
Dis Markers; 2022; 2022():2478551. PubMed ID: 35692888
[TBL] [Abstract][Full Text] [Related]
11. FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.
Liu T; Zhang H; Sun L; Zhao D; Liu P; Yan M; Zaidi N; Izadmehr S; Gupta A; Abu-Amer W; Luo M; Yang J; Ou X; Wang Y; Bai X; Wang Y; New MI; Zaidi M; Yuen T; Liu C
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7683-7688. PubMed ID: 28674022
[TBL] [Abstract][Full Text] [Related]
12. SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.
Yin H; Qin C; Zhao Y; Du Y; Sheng Z; Wang Q; Song Q; Chen L; Liu C; Xu T
Clin Transl Oncol; 2017 Aug; 19(8):1035-1044. PubMed ID: 28258492
[TBL] [Abstract][Full Text] [Related]
13. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
14. FSIP1 regulates autophagy in breast cancer.
Liu C; Sun L; Yang J; Liu T; Yang Y; Kim SM; Ou X; Wang Y; Sun L; Zaidi M; New MI; Yuen T; Guo Q
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):13075-13080. PubMed ID: 30509973
[TBL] [Abstract][Full Text] [Related]
15. DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer.
Zhang S; Zhang G; Guo H
Tumour Biol; 2017 Jun; 39(6):1010428317703822. PubMed ID: 28621231
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors.
Chapman KB; Prendes MJ; Kidd JL; Sternberg H; West MD; Wagner J
Biomark Med; 2013 Aug; 7(4):601-11. PubMed ID: 23905897
[TBL] [Abstract][Full Text] [Related]
17. Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma.
Zhang W; He W; Shi Y; Zhao J; Liu S; Zhang F; Yang J; Xie C; Zhang Y
Int J Oncol; 2017 Jan; 50(1):173-184. PubMed ID: 27909716
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between expression of long non-coding RNA ZXF1 and prognosis of lung adenocarcinoma and its potential molecular mechanism].
Pan GF; Zhou XF; Zhao JP
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):102-108. PubMed ID: 28219204
[No Abstract] [Full Text] [Related]
19. High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.
Li C; Cui Y; Liu LF; Ren WB; Li QQ; Zhou X; Li YL; Li Y; Bai XY; Zu XB
Clin Genitourin Cancer; 2017 Oct; 15(5):570-576. PubMed ID: 28648755
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-497 upregulation inhibits cell invasion and metastasis in T24 and BIU-87 bladder cancer cells.
Wei Z; Hu X; Liu J; Zhu W; Zhan X; Sun S
Mol Med Rep; 2017 Aug; 16(2):2055-2060. PubMed ID: 28656286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
